Merge Healthcare Incorporated (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that NorthWise Services (NWS) has partnered with Merge and selected eClinicalOS® to collect, manage and report on clinical trials data across all studies.
NWS is a specialist CRO offering services in data management, statistics and medical writing. Its services are complementary to the offerings of Merge, which has allowed for a strong and active working partnership to develop.
“NWS has always supported products at the forefront of eClinical technology, but in the past this tended to be separated into different software tools for EDC, ePRO, IVR, etc.,” explained Dr. Philip North, Managing Director of NorthWise Services. “It is therefore very appealing now to be able to access a wide range of eClinical functions on a single web-based platform, with just one user login and password.”
Recognizing the potential benefits of eClinicalOS in collecting, managing and reporting clinical trials data across all phases, NWS has arranged to have its own eClinicalOS certified study builder, who can now build studies for clients using eClinicalOS.
“We were pleased with how easy it was for our study builder to become qualified and certified in the use of eClinicalOS,” continued Dr. North. “Merge provided NWS access to eClinicalOS in a sandbox environment during the self-training process. Because of this, the qualification was quickly and entirely achieved, using only the extensive online training materials available within eClinicalOS. The built-in training materials were intuitive and thorough. Our staff did not require any additional help from Merge – though that would have been available if needed.”
Cost transparency using eClinicalOS’s self-service quoting tool was also a benefit to NWS.
“The cost calculator tool has been very valuable,” added Dr. North. “Not only is Merge eClinicalOS competitive in the eClinical marketplace, but this tool allows us to remain competitive when bidding on a new study with our sponsor clients.”
“With eClinicalOS, NWS has deep visibility into the cost of its studies,” said Justin Dearborn, President of Merge Healthcare. “We designed a cost calculator into the system which allows our clients to generate their own quotes and create budget scenarios in real-time. This provides them with the decision support tools to balance options and costs.”
Merge eClinicalOS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more efficiently than ever before. It delivers built-in study templates, libraries and reports to help users create studies quickly and manage them effectively without technical assistance. Merge eClinicalOS works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality.
About Merge Healthcare
Merge is a leading provider of clinical systems and innovations that seek to transform healthcare. Merge’s enterprise and cloud-based solutions for image intensive specialties provide access to any image, anywhere, any time. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health. With solutions that are used by providers and consumers and include more than 20 years of innovation, Merge is helping to reduce costs and improve the quality of healthcare worldwide. For more information, visit merge.com.
About NorthWise Services
NorthWise Services (NWS) was founded in January 2001, and has main offices at the Kent Science Park in Sittingbourne, UK. NWS offers a range of services, including data management, statistics, and medical writing, to the pharmaceutical, biotechnology and other industries, and other services and products through strategic working alliances. For more information, visit northwiseservices.com.
Cautionary Notice Regarding Forward-Looking Statements
The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.